Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.67 |
| ▸ | TTK | P33981 | 6/20 | 0.67 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.30 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9940574 | 0.99 | PIM1 (0.66) | PIM1TTKPIM2ADORA3HASPIN | |
| SCHEMBL10220018 | 0.86 | PIM1 (0.56) | PIM1TTKPIM2HASPINCFD | |
| Hydrochloric Acid SCHEMBL9940892 | 0.85 | PIM1 (0.55) | PIM1TTKPIM2HASPINCFD | |
| SCHEMBL9941041 | 0.84 | PIM1 (0.53) | PIM1TTKPIM2HASPINCFD | |
| SCHEMBL9940630 | 0.83 | PIM1 (0.63) | PIM1TTKPIM2HASPINCFD | |
| SCHEMBL9940889 | 0.81 | PIM1 (0.54) | PIM1TTKPIM2ADORA3HASPIN | |
| SCHEMBL10220017 | 0.81 | PIM1 (0.52) | PIM1TTKPIM2HASPINCFD | |
| SCHEMBL15370251 | 0.80 | PIM1 (1.00) | PIM1TTKPIM2HASPINDUSP10 | |
| SCHEMBL9940633 | 0.80 | PIM1 (0.53) | PIM1TTKPIM2ADORA3HASPIN | |
| SCHEMBL9941058 | 0.80 | PIM1 (0.57) | PIM1TTKPIM2HASPINMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | claimed |
| EP-2614065-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-07-17 | — | — | EP | claimed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | claimed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | claimed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885TTK 291/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.